Herpes Zoster (Shingles) Market Report Forecasts Impressive Growth by 2024
Browse through Herpes Zoster (Shingles) Market report to know what factors will shape the market by 2024: http://www.transparencymarketresearch.com/herpes-zoster-market.html
Shingles is most common in old age people as compared to young age generation because they have weak immune system that might develop due to fever, stress, certain medications or injury. Similarly, people undergoing chemotherapy or radiation therapy or taking medications such as steroids that weaken immune system are more prone to be victim of shingles infection. According to the Centers for Disease Control and prevention (CDC) in the United States every year more than 1 million cases of herpes zoster are estimated. Similarly, approximately 1 out of every 3 people in the United States develops herpes zoster once in their lifetime. Thus, for the diagnosis of herpes zoster laoboratory tests are performed which majorly detects VZV-specific IgM antibody in the blood. This antibody occurs in the blood stream only during the time of chicken pox or herpes zoster. After the diagnosis of the disease certain medications also prescribed for the treatment that include antiviral medications (acyclovir, famciclovir and valcyclovir), narcotic medications, anti-inflammatory medications, antihistamines (Benadryl), anticonvulsants or zostrix cream and others.
Furthermore, for the prevention of viral infection vaccines are prescribed to prevent an individual from developing severe shingles complications or symptoms. Zostavax is a live vaccine that is marketed for VZV. These vaccines are recommended by the Advisory Committee on Immunization Practices (ACIP), U.S. to reduce the risk of shingles and its associated pain in people aged over 60 years. In England annual incidence of shingles for those aged 70 years to 79 years is anticipated to be around 800 to 900 cases per 100,000 people.
Geographically, North America is the leading geography followed by the European market. Market growth of these regions is accounted due to presence of large base of population suffering from shingles. Asia-Pacific and Rest of the world region in the future are expected to emerge as fastest growing economies in this market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Herpes Zoster (Shingles) Market by 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14999
Herpes Zoster Market Key Players
Major players that are involved in the development of therapeutics against shingles include Astellas Pharma, Inc. GlaxoSmithKline PLC, Foamix Ltd., Epiphany Biosciences and Merck & Co.
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Herpes Zoster (Shingles) Market Report Forecasts Impressive Growth by 2024 here
News-ID: 552691 • Views: 422
More Releases from TMR - Research Reports
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment
More Releases for Herpes
Herpes Markers Testing Market
According to the latest market report published by Persistence Market Research titled ‘Herpes Marker Testing Market: Global Industry Analysis (2012 – 2016) & Forecast (2017 – 2025)’, the global market is expected to be valued at US$ 481.8 Mn by 2025 and expand at a CAGR of 6.1% over the forecast period (2017–2025). The overall market is anticipated to grow 1.7x in terms of value over the forecast period. Market Dynamics Certain
Genital Herpes - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Genital Herpes - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H2 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape. Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused
Herpes Zoster market Pipeline Review, H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H2 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape. Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and
Global Herpes Treatment Market Research Report 2017
Report Hive Market Research Released a New Research Report of 100 pages on Title " Global Herpes Treatment Market Research Report 2017 "with detailed Analysis, Forecast and Strategies. In this report, the global Herpes Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented
Genital Herpes - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Genital Herpes - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape. Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused
Herpes Zoster (Shingles) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Herpes Zoster (Shingles) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape. Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster